Business
Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations
Calgary, Alberta--(Newsfile Corp. - May 19, 2022) -   Hemostemix Inc. (TSXV: HE...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Pete Pavlin, P.Eng., Vice-President OperationsCalgary, Alberta--(Newsfile Corp. - May 19, 2022) -   Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\") is pleased to announce the appointment of Mr. Peter Pavlin, P.Eng. to the position of Vice President Operations.Mr. Pavlin earned his Bachelor of Applied Science and Master of Engineering degrees in Mechanical Engineering from the University of Toronto, Canada's top ranked engineering school. He has held progressive positions managing and directing cross-functional engineering teams that have produced innovative solutions in response to diverse technical challenges. As a consultant to Vadeko International, he applied state of the art real-time tracking technology, evaluating the performance of the NASA Space Shuttle ASRM (Advanced Solid Rocket Motor) refurbishing robot system.As the Director of Advanced Manufacturing for Stackpole International, Mr. Pavlin directed the development of a novel computer-based, powder metal compaction simulator, streamlining high-volume parts production.As the Mechanical Engineering Manager for Sterner Automation, Peter led a team of mechanical engineers that pioneered automated material handling and testing of automotive seating systems and at Byrne Engineering, he led a team of engineers in the refurbishment of numerous critical transportation infrastructure movable bridge systems.Most recently as General Manager of Engineering for Weir Minerals Canada, Pete directed the development and evolution of Weir's massive marine and land-based modular pumping systems, setting a new standard in the global mining marketplace. \"Pete is a great addition to our team and he is no stranger to our technology, as he conducted the feasibility study of automated production of ACP-01 in 2008. His knowledge and experience in developing highly engineered, commercially focused, automated production systems is a huge advantage as we move to scale production,\" stated Thomas Smeenk, CEO. \"I'm delighted to join Hemostemix at this pivotal and exciting time for the company. I look forward to collaborating with our diverse, experienced team of medical professionals and business leaders to operationalize and scale production,\" stated Mr. Pavlin. ABOUT HEMOSTEMIXHemostemix is a publicly traded autologo...